Who makes Echothiophate Iodide 0.03% Ophthalmic Solution?

Echothiophate Iodide 0.03% Ophthalmic Solution is developed by Danbury Eye Physicians & Surgeons, PC.

What development phase is Echothiophate Iodide 0.03% Ophthalmic Solution in?

Echothiophate Iodide 0.03% Ophthalmic Solution is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Echothiophate Iodide 0.03% Ophthalmic Solution

Danbury Eye Physicians & Surgeons, PC · FDA-approved active Small molecule Quality 2/100

At a glance

Generic name	Echothiophate Iodide 0.03% Ophthalmic Solution
Also known as	Phospholine Iodiede 0.03% ophththalmic solution
Sponsor	Danbury Eye Physicians & Surgeons, PC
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Echothiophate Iodide for the Prevention of Progression of Myopia (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Echothiophate Iodide 0.03% Ophthalmic Solution CI brief — competitive landscape report
Echothiophate Iodide 0.03% Ophthalmic Solution updates RSS · CI watch RSS
Danbury Eye Physicians & Surgeons, PC portfolio CI